NOVABRIDGE BIOSCIENCES

NBPNASDAQ

🏆 #3019 by market capEarnings Aug 18US Equity

$663.86▲ $40.16 (+6.05%)

Simulated price

1h—

24h▲ 6.0%

7d▲ 40379.3%

14d▲ 41133.5%

30d▲ 35400.5%

1y▲ 17233.2%

🏦Market Cap

$204M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

100.0%

High

💵FCF Margin

—

⚖️P/S Ratio

4.3x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $661.55 – $667.06
52-Week Range: $1.46 – $6.79
Volume: $3.75B
Avg Volume: $3.24B
Shares Outstanding: 266.0M
Next Earnings: Sep 11, 2026

Fundamentals Snapshot

Annual Revenue: $47M
Last Q Revenue: $13M
P/E Ratio: —
P/S Ratio: 4.3x
EPS (TTM): $-0.19
Dividend Yield: —

Why Investors Own NBP

✓High-growth profile — revenue up +21.1% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$47M▲ +20.0% YoY

Gross Margin (TTM)

44.0%▲ +3.1% YoY

Operating Income (TTM)

$16M▲ +20.0% YoY

Free Cash Flow (TTM)

$10M▲ +20.0% YoY

About NOVABRIDGE BIOSCIENCES

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

🦦